Scilex Holding Company, Inc. - SCLX Net earnings per one share for the last twelve months

Scilex Holding Company (SCLX) faces financial instability due to substantial debt, patent disputes, and reliance on a single drug, as evidenced by the asset's market value shown on this chart, where the EPS TTM is -309.70. The company generates revenue from the sale of nasal sprays and patches for the management of chronic pain without the use of opioids. Despite the demand for ZTlido, maintaining market positions requires significant investments in promotion and insurance coverage.
SCLX (Scilex Holding): analytical breakdowns and indicator data

The robotization of medicinal patch packaging lines at Scilex Holding Company (SCLX) optimizes costs, directly impacting profitability. Analyzing the rolling annual growth of net income per share allows for the tracking of this efficiency between quarterly reports. This metric continuously compares earnings over the last 12 months relative to the current price, revealing hidden market imbalances. Such extremes serve as a signal for a potential revaluation or an upcoming price reversal.